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Neuropsychiatric fluctuations in Parkinson’s disease (PD) are frequent and disabling.
One way to investigate them is to assess the ability to inhibit distractive emotional
information by a modified emotional Stroop (ES) task. We compared non-depressed,
non-demented PD patients with healthy controls. During an acute levodopa challenge,
patients performed a modified ES task during functional MRI and a neuropsychological
assessment including Visual Analog Mood (VAMS) and Apathy scales. Ten patients and 12
controls completed the study. The VAMS scores were significantly improved by the acute
intake of levodopa (p = 0.02), as was the apathy score (p = 0.03). Negative ES task (i.e.
fearful facial expressions with the words “happy” or “fear” written across them), induced
a lengthening of the mean reaction time during the incongruent trials compared with the
congruent trials in controls (relative difference = 2.7%, p < 0.001) and in ON patients
(relative difference = 5.9%, p < 0.001), but not in OFF patients (relative difference = 1.7%,
p = 0.28). Controls and ON patients displayed greater activation than OFF patients within
the right pregenual anterior cingulate cortex (pACC), an area specifically involved in
emotional conflict resolution (p < 0.001 and p < 0.008 respectively, k > 5 uncorrected).
No difference in the activation of the pACC was found between controls and ON
patients, suggesting a normalization of the activation following levodopa administration.
These results suggest that emotional conflict processes could be dopamine-dependent.
Pregenual ACC hypoactivation could be directly due to the degeneration of dopaminergic
mesocorticolimbic pathway. Our results propose that neuropsychiatric fluctuations in PD
patients could be partially explained by pACC hypoactivation and that adjustments of
dopaminergic medication might be helpful for their treatment.
Keywords: emotional stroop, dopamine, Parkinson’s disease, cingulate cortex, non-motor fluctuations
Abbreviations: ACC, anterior cingulate cortex; BA, Brodmann area; BDI, Beck
Depression Inventory; BOLD, Blood-Oxygen-Level Dependent; C, congruent trial;
CI, confidence interval; DRS, Dementia Rating Scale; ES, emotional Stroop; FAB,
Frontal Assessment Battery; FOV, field of view; fMRI, functional MRI; HC, healthy
controls; I, incongruent trial; k, cluster size; LEDD, levodopa-equivalent daily
dosage; MDD, major depressive disorder; MNI, Montreal Neurological Institute;
N, negative facial expression; NMF, non-motor fluctuations; OFC, orbitofrontal
cortex; OCD, obsessive-compulsive disorder; P, positive facial expression; PTSD,
posttraumatic stress disorder; R1, region 1; R2, region 2; rACC, rostral anterior
cingulate cortex; RT, reaction time; SAS, Starkstein Apathy Scale; SD, standard devi-
ation; t, t-value (against chance level); TE, time echo; TR, time repetition; UPDRS,
Unified Parkinson’s Disease Rating Scale; VAMS, Visual Analog Mood Scale; VTA,
Ventral Tegmental Area.
INTRODUCTION
Although non-motor fluctuations (NMF) occur frequently
throughout the course of Parkinson’s disease, their prevalence is
often underestimated. They can be more disabling than motor
symptoms. NMF frequently manifest in relationship to motor
fluctuations (Witjas et al., 2002) and fluctuate in parallel with
them (Storch et al., 2013). Forms of NMF include neuropsy-
chiatric, dysautonomic, and sensory symptoms (Riley and Lang,
1993). Neuropsychiatric fluctuations encompass apathy, anxiety,
sadness, slowness of thinking, fatigue during drug-off condition,
and mood elation with euphoria and increased alertness in
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drug-on state (Witjas et al., 2002; Fox and Lang, 2008; Lhommée
et al., 2012). Previous publications have demonstrated that
mood and anxiety fluctuations are related to levo-dopa dos-
ing (Friedenberg and Cummings, 1989; Maricle et al., 1995b;
Richard et al., 2005). Different mechanisms have been proposed
to explain neuropsychiatric fluctuations such as mesocorticol-
imbic dopaminergic denervation underlying off-period related
neuropsychiatric symptoms (Thobois et al., 2010), sensitization
related to severity of the mesocorticolimbic lesion in combination
with pulsatile dopaminergic treatment with levodopa (Voon et al.,
2011; Castrioto et al., 2013) and/or relatively selected stimula-
tion ofmesocorticolimbic dopamine D3 receptors with dopamine
agonists (Thobois et al., 2013). Both mood and anxiety disorders
have a high prevalence among parkinsonian patients (Reijnders
et al., 2008; Dissanayaka et al., 2010). Certain authors suggest that
their impact on quality of life is more important than the impact
of motor signs (Schrag, 2006; Chaudhuri and Schapira, 2009).
In the “NMF in Parkinson’s disease study,” anxious and depres-
sive symptoms were highly associated with drug-off state. Beck
Depression Inventory (BDI) scores, obtained while parkinsonian
patients were on chronic dopaminergic medication, only corre-
lated with depression severity in drug-off but not in drug-on state,
suggesting that depression scoring in fluctuating patients mainly
reflects the mood in drug-off state during NMF (Storch et al.,
2013). Consequently, a better understanding of neuropsychiatric
fluctuations physiopathology seems necessary in order to improve
parkinsonian patient’s mood symptoms management and quality
of life.
Patients with depression or anxiety disorders show a higher
sensitivity toward negatively valenced stimuli, which results in
slower processing of negative emotional information (Williams
and Nulty, 1986; Becker et al., 2001). A method for investigating
inhibition of distractive emotional information (i.e. emotional
interference) is the emotional Stroop (ES) task (Williams et al.,
1996). Variants of the ES task have been developed such as the
word-face Stroop task (Stenberg et al., 1998) or the modified ES
task (Etkin et al., 2006). In this latter task, subjects are asked to
identify the affect of faces with fearful or happy expressions while
ignoring the words “happy” or “fear” written across them. Words
are either congruent or incongruent with faces. Emotional con-
flict arises when the word is not in agreement with the facial
expression. It induces an emotional interference resulting in a
decision-making slowdownwith slower reaction time to name the
affect of faces if the emotion of the word written across the face
is incongruent with the facial expression. Serra-Mestres and Ring
(2002) demonstrated that non-depressed parkinsonian patients
presented with significantly greater emotional interference than
did controls, despite matching for depression score, supporting
the hypothesis that non-depressed parkinsonian patients were
more vulnerable to the interfering effects of negative emotional
stimuli. This vulnerability could be a factor contributing to the
increased risk of developing depression in parkinsonian patients,
because in the presence of sadness, patients will remain in that
state for longer periods.
Neuroimaging studies suggested that the pregenual part of
the anterior cingulate cortex (ACC), also known as the rostral
anterior cingulate cortex (rACC), plays a major role in ES task
performance (Whalen et al., 1998; Etkin et al., 2006; Egner et al.,
2008). The rACC is located in the medial surface of the brain
and is anterior to the genu of the corpus callosum. It is a key
structure for the integration of emotion and cognition (Pessoa,
2008). It is considered to be a part of the affective subdivision
of the ACC (together with the subgenual ACC) because it has
connections with the limbic and paralimbic regions, such as the
amygdala, the orbitofrontal cortex (Devinsky et al., 1995) and
the nucleus accumbens (Johansen-Berg et al., 2008). The rostral
ACC is specifically associated with the resolution of emotional
conflict (i.e., overcoming of conflict), whereas the lateral pre-
frontal cortex resolves exclusively non-emotional conflict (Egner
et al., 2008). Conversely, a common area of the dorsal ACC,
which is located in the posterior region of this structure, detects
and signals the occurrence of conflict in information processing
(Botvinick et al., 1999; Kerns et al., 2004). This region is acti-
vated by both emotional and non-emotional conflict monitoring
(Egner et al., 2008).
The neurotransmission involved in ES processes is largely
unknown. The ACC is involved in the regulation of attention
(Posner and DiGirolamo, 1998). As it has been suggested that
dopaminergic signals serve to draw attention to salient events of
all sorts (Gray et al., 1997) and that dopamine is a critical compo-
nent involved in the attribution of salience of attractive or aversive
valence to stimuli (Bressan and Crippa, 2005), it is possible that
dopamine plays a role in ES processes. Parkinson’s disease is pri-
marily due to degeneration of dopaminergic neurons and offers
the opportunity to investigate the pharmacological manipulation
of the dopaminergic system in humans. Abnormal behavioral
performances to the ES task have been found in Parkinson’s
disease (Serra-Mestres and Ring, 1999, 2002) and in psychi-
atric conditions such as cocaine or heroin addiction in which
dopaminergic dysfunction is well demonstrated (Marissen et al.,
2006).
We hypothesized that dopamine would play a role in emo-
tional interference processes and that mood disturbances during
neuropsychiatric fluctuations in parkinsonian patients could be
explained by an abnormal rACC functioning. We assessed fluctu-
ating non-depressed parkinsonian patients during their drug-on
and drug-off states while performing a modified ES task dur-
ing functional MRI (fMRI), in order to better understand the
pathophysiology of neuropsychiatric fluctuations.
MATERIALS AND METHODS
PARTICIPANTS
Patients were recruited from the Grenoble University Hospital
Movement Disorders Clinic. The selection criteria were as follows:
presence of clinically diagnosed Parkinson’s disease according to
the United Kingdom Parkinson’s Disease Society Brain Bank clin-
ical criteria for Parkinson’s disease (Hughes et al., 1992), presence
of motor and non-motor fluctuations, age < 70 years, the ability
to tolerate the experimental period in the MRI machine during
a drug-off state (i.e., ≥11 h after the patient’s last dopaminergic
drug dose the night before) and during a drug-on state (i.e., 1 h
after a dose of levodopa which efficiently controls parkinsonian
symptoms without disabling dyskinesia) and the absence of a con-
traindication to an MRI. The patients were compared to healthy
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volunteers who were recruited from the community. Healthy con-
trols (HC) had no history of neurological or psychiatric disorders.
They were chosen tomatch the patient group as closely as possible
for age, sex, and education level.
Exclusion criteria for both groups were: the presence of
dementia as indicated by a score of ≤130 on the Mattis Dementia
Rating Scale (DRS) (Mattis, 1976; Schmidt et al., 1994) or a
score ≤12 on the Frontal Assessment Battery (FAB) (Dubois
et al., 2000; Kaszás et al., 2012), the presence of moderate to
severe depression as indicated by a score ≥20 on the BDI-II
(Beck et al., 1996), the presence of psychosis, and/or the pres-
ence of impaired face recognition as indicated by a score < 41
on the long-form of the Benton Recognition Test (Levin et al.,
1975; Benton, 1994). Subjects with fMRI-related issues (i.e. unsat-
isfactory picture quality caused by participants moving within
the scanner during acquisition or other scanner-specific tech-
nical complications) were excluded. The Ethics Committee of
the Grenoble University Hospital approved the study. After a
complete description of the study, the participants gave written
informed consent in accordance with the Grenoble University
Hospital Review Board guidelines and the Declaration of
Helsinki.
PROCEDURES
Each participant completed a modified ES task during fMRI fol-
lowed by a neuropsychological assessment. Each parkinsonian
patient was studied twice in a counterbalanced manner dur-
ing a levodopa challenge where the drug-off and the drug-on
states were performed on two consecutive mornings. The drug-
off state followed an overnight withdrawal of all antiparkinsonian
drugs. The drug-on state was performed in a fasting state in
order to improve levodopa absorption and to enable more pre-
cise timing of the maximum therapeutic effect. Levodopa was
administrated orally using a levodopa-benserazide dispersible
formulation. For each patient, the dose of levodopa used for
the challenge was calculated as 100% of his levodopa equivalent
first morning dose. The equivalent dose was calculated accord-
ing to Tomlinson et al. (2010). We decided against the use of
suprathreshold doses of levodopa (i.e., 130–150% of the levodopa
equivalent first morning dose) in order to not prime dyskine-
sias, which could have induced fMRI movement artifacts, and
to avoid modifying cognition. Before each MRI scan, all patients
underwent a neurological examination to rate the severity of their
motor function using theUnified Parkinson’s Disease Rating Scale
(UPDRS) motor rating items 18–31 in drug-on and drug-off con-
ditions (Fahn and Elton, 1987). Levodopa and dopamine agonist
doses were expressed as total levodopa-equivalent daily dosage
(LEDD) (Tomlinson et al., 2010). All participants were asked to
refrain from nicotine and caffeine for ≥4 h prior to the fMRI
studies.
fMRI stimuli
The modified ES task consisted of 136 presentations of black
and white happy and fearful facial expression photographs drawn
from the Montreal Set of Facial Displays of Emotion (Beaupré
and Hess, 2005). This battery consists of emotional facial expres-
sions by men and women of European, Asian, Hispanic and
African decent. Each expression had been coded according to
the Facial Action Coding System (Ekman and Friesen, 1978) to
assure identical expressions across actors. The words “FEAR” or
“HAPPY” were prominently written in red bold “Arial” size 45,
centered on the middle of faces (i.e., on the “nose” position).
The face–word association created either a congruent condition
(32 happy faces with the word “HAPPY,” 32 fearful faces with
the word “FEAR”) or an incongruent condition (32 happy faces
with the word “FEAR,” 32 fearful faces with the word “HAPPY”)
(Figure 1). Eight additional faces in the incongruent condition
(happy faces with the word “FEAR”) were added, in order to
obtain 136 presentations to allow the construction of a pseu-
doaleatory design with blocks of 17 pictures presented 8 times.
All faces were resized to 1024 × 717 pixels and size was con-
trolled by e-prime2 software (100% of the initial size). Gender,
ethnic group (Caucasian, Asian, African and Hispanic), and facial
expressions (fear and happiness) were counterbalanced across
conditions (congruent or incongruent) and across trial sequences.
There were neither direct repetitions of the same face with vary-
ing word distracters, in order to avoid negative priming effects,
nor direct repetitions of exact face-word-distracter combination,
in order to avoid repetition priming effects (Etkin et al., 2006).
All conditions (i.e., congruent and incongruent) were displayed
in pseudorandom order.
Emotional stroop task
Participants were instructed to judge as fast and as accurately as
possible whether facial expressions represented fear or happiness
while ignoring the word. After receiving instructions, partici-
pants underwent a short training session immediately prior to
the experiment, with items that were not shown during the real
experiment.
The ES task was presented with the E-Prime 2 software (E-
Prime Psychology Software Tools Inc., Pittsburgh, USA) and was
displayed on a back-projection screen that was viewed by the sub-
jects via a mirror attached to the head-coil. Each trial began with a
stimulus (face-word association) displayed for 1000ms, followed
by a fixation cross for 2000ms (interstimulus interval of 3000ms)
(Figure 2). The responses (fear and happy) were recorded by
means of two response keys pressed by the index finger of the
subject’s dominant hand. The mean response time and percent-
age of correct responses were recorded for each participant. The
duration of the ES task was 7min.
FIGURE 1 | Examples of stimuli used in the modified emotional Stroop
task.
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FIGURE 2 | Example timeline used in the modified emotional Stroop task fMRI paradigm.
fMRI data acquisition
BOLD fMRI data were collected while subjects performed
the ES task in a 3Tesla Bruker Medspec S300 MRI scanner
using a gradient–echo T2∗–weighted Echo Planar Imaging (EPI)
sequence covering 39 axial, interleaved slices (3.2mm thick,
0mm gap), beginning at the cerebral vertex and encompass-
ing the entire cerebrum and the cerebellum (time repetition
(TR) = 2500ms; time echo (TE) = 30ms; flip angle = 77◦;
field of view (FOV) = 216 × 216mm2; matrix = 72 × 72; voxel
size = 3 × 3 × 3.2mm). Six dummy scans were done before
image acquisition to avoid the effects of signal saturation. All
scanning parameters were selected to optimize the quality of
the BOLD signal while maintaining a sufficient number of
slices to acquire whole-brain data. For structural whole-brain
images, three-dimensional T1–weighted sagittal images of the
whole-brain were also acquired (TR = 2500ms; TE = 4.3ms;
TI = 908.1ms; flip angle = 8◦; FOV = 256 × 224 × 176mm3;
voxel size = 1.33 ×1.75 × 1.37mm3).
Neuropsychological assessment
All participants performed a neuropsychological evaluation
including the Mattis DRS for global cognitive assessment, the
FAB for dysexecutive dysfunction assessment, the BDI for depres-
sion assessment, the State-Trait Anxiety Inventory for Adults
(Spielberger, 1983) to assess their anxiety level and the Benton
Recognition Test for facial perception assessment. Patients con-
tinued their standard dopaminergic medication during this eval-
uation. The presence and the intensity of NMF were evaluated
with the Ardouin Scale (Ardouin et al., 2009). The NMF, which
patients experienced in daily life on their usual treatment, were
assessed by adding the two items “drug-on NMF” and “drug-off
NMF.” A score≥ 1 was taken as indicative of the presence of NMF.
During their drug-off and drug-on states, participants
performed a second neuropsychological assessment in a coun-
terbalanced manner, comprising a Visual Analog Mood
Scale (VAMS) (Norris, 1971) to measure the acute lev-
odopa effects on patient’s subjective states, an Starkstein
Apathy Scale (SAS) where a score ≥ 14/42 corresponded
to the diagnosis of apathy (Starkstein et al., 1992), and
an Ekman Facial Affect Test (Ekman and Friesen, 1976)
to assess the ability to identify facial expressions of emo-
tions (happiness, sadness, fear, disgust, surprise, anger,
neutral).
STATISTICAL ANALYSIS
Statistical analysis of behavioral data
Accuracy (% of correct responses) and reaction time (RT) laten-
cies were recorded during the fMRI experiment. Mean task
accuracy was calculated as the average percentage of trials cor-
rectly identified relative to the sum of trials. Error trials (wrong
answers and omissions) were excluded from the RT analysis.
Different conditions were distinguished: incongruent trials with
negative or positive faces and congruent trials with negative
or positive faces. RT was log transformed to normalize the
data. Differences in performances between groups (HC, drug-
on and drug-off patients), congruency (congruent or incon-
gruent) and emotion (negative or positive faces) were assessed
using linear mixed effects models with a random effect on sub-
ject. Interaction terms between congruency and emotion, and
between congruency and group were introduced in the model.
ES effect was defined as a lengthening of the mean RT dur-
ing the incongruent trials compared with the congruent tri-
als. Statistical significance was assessed at the 0.05 level for all
analyses.
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fMRI statistical analysis
Data analysis was performed by using the general linear model
as implemented in SPM8 (Wellcome Department of Imaging
Neuroscience, London, UK) where each event is modeled using a
hemodynamic function model. Data analysis started with several
spatial pre-processing steps. First, the functional volumes were
time-corrected with the second slice as reference. Subsequently,
all volumes were realigned to correct head motion using rigid
body transformations. After discarding the four first slices, the
first volume of the fMRI session was taken as the reference vol-
ume. To correct for interaction between head movements and
EPI distortions, unwarping was performed by using the indi-
vidually acquired fieldmaps (Andersson et al., 2001). Weighted
anatomical volume was co-registered to mean images created by
the realignment procedure and was normalized to the Montreal
Neurological Institute (MNI) space. The anatomical segmenta-
tion parameters were subsequently used for the normalization of
anatomical and functional volumes. Finally, each functional vol-
ume was smoothed by an 8-mm Full Width at Half Maximum
Gaussian kernel to ameliorate differences in intersubject localiza-
tion. Time series for each voxel were high-pass filtered (1/128Hz
cutoff) to remove low-frequency noise and signal drift.
With regards to congruence [Congruence (C) vs.
Incongruence (I)] and emotion [Positive for facial expres-
sion of happiness (P), Negative for facial expression of fear (N)]
for each participant, we defined four experimental conditions
(CP, CN, IP, IN). These conditions were modeled as four regres-
sors and convolved with the canonical form of the hemodynamic
response function. Moreover, movement parameters derived
from realignment corrections (3 translations and 3 rotations)
were also taken into account in the design matrix to remove the
movement-related variance.
Next, several statistical analyses were performed. At the first
level analysis (within-group comparisons), the following effects
were evaluated: the ES effect with all faces (I vs. C) [I (P+N) vs.
C (P+N)] as well as the ES effect with only the positive faces ana-
lyzed [I (P) vs. C (P)] and the ES effect with only the negative
faces analyzed [I (N) vs. C (N)] (i.e., Negative ES contrast), using
a one-sample t-test, in order to identify cerebral regions involved
in emotional conflict. At the second level analysis (between-group
level), we performed a random-effect between-group analysis by
using paired t-tests (Friston et al., 1998) according to the Negative
ES contrast defined at the individual level analysis in order to
characterize cerebral differences between parkinsonian patients in
their drug-off and drug-on states, and HC.
RESULTS
Twelve parkinsonian patients and twelve HC were included in the
study. One patient was not able to complete the SE task in theMRI
machine during his drug-off state because of a painful dystonia
and was excluded from all analyses. Another patient was excluded
because of unsatisfactory picture quality caused by participant
movements during image acquisition in the MRI. Consequently,
data from ten patients (seven males, age range: 51–66 years, mean
age: 60, SD: 4.2) and twelve HC (8 males, age range: 46–69 years,
mean age: 60.1, SD: 6.4) were included in the analyses. Clinical
characteristics of each group are reported in Table 1.
Table 1 | Demographic and clinical characteristics of participants.
Patients Controls p-value
(n = 10) (n = 12)
Age (years) 60±4.2 60.1±6.4 ns
Sex ratio (male:female) 7:3 8:4
Education duration
(years)
10.7±5 12.4±5.2 ns
Disease duration (years) 9±3.1
Levodopa-equivalent
daily dose (mg/day)
917.7±367.6
Drug-off UPDRS motor
score (/108)
33.8±10.8
Drug-on UPDRS motor
score(/108)
11.4±7.4*
Non-motor fluctuation
Ardouin score (/8)
2.1±0.9
Mattis DRS score**
(/144)
138.2±4.5 141.2±2.0 ns
FAB** (/18) 15.8±1.8 17.3±0.9 0.03
Benton** (/54) 47.3±2.3 47.6±2.5 ns
BDI** (/63) 11.5±7.9 5.4±5.5 0.04
STAI state** (/80) 34±17.1 24.5±4.4 ns
STAI trait** (/80) 37.6±8.4 32.75±6.8 ns
Values are expressed as mean (±SD) scores. BDI, beck depression inventory;
FAB, frontal assessment battery; Mattis DRS, dementia rating scale; n = num-
ber of participants; ns = non-significant; STAI, State-Trait Anxiety Inventory for
Adults; UPDRS motor score, motor scale of Unified Parkinson’s Disease Rating
Scale.
p significant if <0.05 when compared with controls (Student test for age and
education level; Mann-Whitney test for score on the Mattis, FAB, Benton, BDI,
STAI tests). *p = 0.005 for difference between the drug-off and drug-on UPDRS
motor scores (Wilcoxon’s test for paired data). **Scores obtained from patients
on chronic dopaminergic medication.
All patients were on dopamine replacement medications.
Patients and HC did not statistically differ in terms of age, edu-
cation, gender distribution, global cognitive performance, facial
perception or anxiety level. The parkinsonian group scored sig-
nificantly lower on the FAB score than the controls (p = 0.03),
although the averaged score fell within the non-pathological
range (>14/18). Patients scored significantly higher on the BDI
score than the controls (p = 0.04), although the averaged score
fell within the non-depressed range (<12/63). In terms of psy-
chotropic medications, two patients were taking antidepressant
drugs (sertraline or mirtazapine) and four were taking benzo-
diazepines (clonazepam or prazepam). The psychotropic drug
dosage was low and had been stable for at least 6 months in
all patients. None of the control subjects was on psychotropic
medication.
NEUROPSYCHOLOGICAL RESULTS DURING THE LEVODOPA
CHALLENGE
The results are presented in Table 2.
In patients, apathy, as measured by the SAS, significantly
improved with L-dopa intake between drug-off and drug-on con-
ditions (p = 0.03). The affective and asthenia subscores of the
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Table 2 | Neuropsychological characteristics of patients during the
levodopa-challenge.
Group 1 Group 2 p-Value
Drug-off patients Drug-on patients Group 1 vs.
Mean ± SD Mean ± SD Group 2
SAS (/42) 13±2.6 9.5±3.6 0.03
Norris VAS
Asthenia
subscore (/80)
42.3±14.2 12.2±11.2 0.02
Affective
subscore (/80)
25.7±16.3 11.8±8.6 0.02
EKMAN FAT (% CR)
Happiness 100±0 97.1±9.0 ns
Fear 52.8±17.9 64.3±28.7 0.08
Surprise 90±13.6 91.4±10 ns
Sadness 72.84±23.8 62.8±21.5 ns
Disgust 80±23.5 77.1±20.5 ns
Anger 61.4±27 78.6±22.6 ns
Neutral 81.4±16.6 78.6±31 ns
Values are expressed as mean (±SD) scores. Ekman FAT, Ekman Facial Affect
test; ns, non-significant; SAS, Starkstein Apathy Scale; VAS, Visual Analog Mood
Scale; %CR, percentage of correct response. p significant if <0.05 (Wilcoxon
test for paired data for the intra-group comparisons).
VAMSwere significantly improved by the acute intake of levodopa
(p = 0.02). In the drug-off condition, patients had a tendency
to suffer from a selective impairment in facial emotion recog-
nition of fear compared with drug-on patients (p = 0.08) while
there was no difference in correct responses for other emotional
expressions.
BEHAVIORAL DATA
The percentage of correct responses and RT were unavailable
for two drug-off patients, one drug-on patient and one healthy
control, due to technical difficulties during MRI. The mean
task accuracy was not statistically different between the three
groups with an overall accuracy of 80%. The percentage of cor-
rect responses was higher during congruent trials than during
incongruent trials, regardless of the group (p = 0.002). Facial
emotions did not influence the percentage of correct responses.
The reaction time results are presented in Figure 3. In trials
with positive faces, our multivariate mixed effect model indi-
cated a significant effect of congruency on performances in each
group (p < 0.001 for all three groups), with a shorter RT in
the congruent condition compared with the incongruent condi-
tion (in HC, drug-on and drug-off patients, the mean relative
decrease in RT was 8.6% [95%CI: 6.2–11.0], 11.7% [95%CI:
9.1–14.2] and 7.7% [95%CI: 4.9–11.4], respectively). In tri-
als with negative faces, there was a significant effect of con-
gruency on performances in HC (relative difference = 2.7%
[95%CI: 0–5.3], p < 0.001) and drug-on patients (relative dif-
ference = 5.9% [95%CI: 3.1–8.7], p < 0.001). No significant
effect of congruency was found in the drug-off patients in tri-
als with negative faces (relative difference = 1.7% [95%CI: -
1.4–4.6], p = 0.282). The congruence effect was not statistically
FIGURE 3 | SE task behavioral results in controls (HC), drug-off and
drug-on parkinsonian patients. Data are patients’ mean reaction times
expressed in milliseconds (ms) depending on the congruence (I,
incongruent; C, congruent) and facial emotion conditions among the
different groups. The top panel represents trials with negative faces and the
bottom panel represents trials with positive faces. p represents the
statistical significance of the reaction time difference between incongruent
and congruent conditions. Differences were assessed with a linear mixed
effects model.
different between HC and the drug-on or drug-off patients,
whereas it was significantly larger for the drug-on patients com-
pared to the drug-off patients (p = 0.02), regardless of the facial
emotion.
fMRI WITHIN-GROUP COMPARISONS
ES task validation in healthy participants
In HC, the network of cerebral activation elicited by the
Incongruent vs. Congruent [I-C] contrast is shown in Figure 4
and Table 3. A significant activation within the postgenual ACC
(x, y, z MNI coordinates: −9, 16, 20; p < 0.001; k > 5 uncor-
rected) was identified. No significant activation was found in the
rACC or in the amygdala, areas specifically activated in emotional
conflict.
Given that no significant activation was found in the rACC,
and because numerous studies have reported rACC activation
during “sad” ES tasks (i.e., classic ES task using negatively
valenced words written in different ink colors) (Whalen et al.,
1998, for review), we decided to decorrelate the analysis depend-
ing on the emotion of the face. For the contrast [I-C] for negative
faces, the rACC was consistently activated. Two regions, R1 and
R2 were activated within this area (R1: x, y, z MNI coordinates: 6,
50, 4; Brodmann area (BA) = 32; p < 0.001; k > 5 uncorrected,
and R2: x, y, z: 6, 41, 7; BA = 24; p < 0.001; k > 5 uncorrected)
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FIGURE 4 | Brain activation during the emotional Stroop task
(contrast: Incongruent vs. Congruent with all faces) in healthy
subjects. p < 0.001, k > 5, n = 12, uncorrected. LH, left hemisphere; MNI,
Montreal Neurological Institute.
(Figure 5A and Table 4). Other areas less specifically involved
in emotional conflict were also activated, such as the superior
parietal gyrus and the superior temporal gyrus, which has been
involved in the perception of emotion in facial stimuli. The right
inferior frontal gyrus, which has been typically implicated in
go/no go tasks (Aron et al., 2004), was engaged. The amygdala
was not activated.
For the contrast [I-C] for positive faces, a significant activation
within the caudal ACC was found (x, y, z: 0, 14, 30; BA = 24; p <
0.001; k > 5 uncorrected) but not in the rACC (Figure 5B and
Table 5). The contrast [I-C] for positive faces also activated other
areas commonly activated in non-emotional conflict (Egner et al.,
2008), such as the anterior prefrontal cortex, the precuneus, the
lingual gyrus and the inferior parietal gyrus. No suprathreshold
voxels were activated for [C-I] contrast for positive, negative or
all faces.
ES task in parkinsonian patients
Considering the results obtained in HC, we decided to study
the ES effect with the contrast [I-C] for negative faces, as
this was only contrast that activated the rACC. The cere-
bral sites of hemodynamic response during the ES task are
shown in Table 6 for the drug-off patients and in Table 7 for
the drug-on patients. Both patient groups activated less cere-
bral areas and recruited a decreased number of voxels for all
activated brain areas compared to controls. Drug-off patients
exhibited additional areas of activation not seen in HC and
drug-on patients, such as the left superior medial frontal gyrus
(MNI coordinates x = −3, y = 32, z = 46; BA = 8; p < 0.001,
k > 5), the left hippocampus (x = −24, y = −37, z = −8; p <
0.001, k > 5), and the right cuneus (x = 12, y = −94, z =
14; p < 0.001, k > 5). No suprathreshold voxels were acti-
vated for [C-I] contrast for negative faces in any patients
groups.
Table 3 | Brain regions activated during the emotional Stroop task
using all faces in healthy subjects.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (all faces) Cingulate cortex
Anterior
cingulate
L 24 −9, 16, 20 9 4.95
Frontal cortex
Inferior frontal
triangularis
R 45 54, 23, 4 8 4.74
Temporal cortex
Fusiform L 19 −24, −64, −2 9 5
Superior
temporal
L 41 −51, −22, 8 49 7.82
R 41 51, −28, 8 4.75 6
Superior
temporal pole
L 13 −27, 8, 21
L 38 −54, 8, −8 10 4.69
Middle temporal L 19 −45, −64, 14 10 4.69
Inferior temporal R 37 39, −58, −5 6 4.71
Insula R 47 33, 26, 1 32 6.1
Occipital cortex
Middle occipital L 19 −45, −76, 8 5 6.31
Lingual L 17 −24, −76, 11 49 8.27
Calcarine R 19 36, −82, 14 41 6.88
R 18 15, −79, 1 11 4.60
L 18 −6, −70, 14 22 6.83
[I-C] (all faces) No suprathreshold voxels
Cerebral activation locations refer to maximal hemodynamic response sites.
p < 0.001, k > 5, n = 12, uncorrected. Cerebral areas are defined by the
Automatic Anatomical Labeling. BA, Brodmann areas; C, congruent; H, hemi-
sphere; I, incongruent; k, cluster size (number of voxels); L/R, left/right;
MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal, and
dorsoventral.
fMRI BETWEEN-GROUP COMPARISONS
For the contrast [I-C] with negative faces, HC displayed signifi-
cantly greater activation than off-drug patients within the right
rACC (x, y, z: 6, 47, 4.4; BA = 32; p < 0.001; k > 5 uncorrected)
(Figure 6), the right pre- and post-central gyri and the right tha-
lamus (Table 8A). Drug-off patients vs. HC did not yield any
suprathreshold clusters (Table 8B).
Comparisons between HC and drug-on patients (HC vs.
drug-on patients and drug-on patients vs. HC) did not yield
any suprathreshold clusters. Drug-on patients had significantly
greater activation than drug-off patients in the right inferior tem-
poral gyrus (x, y, z: 42, −61, −8; BA = 37; p < 0.001; k > 5
uncorrected), an area involved in visual recognition. No signifi-
cant activation was found in the ACC for a p < 0.001. However,
by reducing the threshold to p < 0.005, drug-on patients dis-
played greater activation than drug-off patients in the left post-
genual ACC (x, y, z: −3, 23, 19; BA = 24; T = 4.28; p < 0.005;
k > 5 uncorrected). For a p < 0.008, drug-on patients displayed
greater activation than drug-off patients in the right rACC (x, y,
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FIGURE 5 | Brain activation during the emotional Stroop task
(contrast: Incongruent vs. Congruent) with separate analysis of
negative (A) and positive (B) faces, in healthy subjects. p < 0.001, k >
5, n = 12, uncorrected. C, congruent; I, incongruent; LH, left hemisphere;
MNI, Montreal Neurological Institute; R1, region 1; R2, region 2; x, y, z:
mediolateral, rostrocaudal, and dorsoventral.
z: 9, 38, 1; BA = 32; p < 0.008; k > 5 uncorrected) (Table 9).
Drug-off patients did not exhibit any suprathreshold clusters
when compared with drug-on patients at a p < 0.001 thresh-
old. No activation was seen in the ACC when the threshold
was increased to p < 0.008 (Table 9). No suprathreshold vox-
els were activated for [C-I] contrast for negative faces in any
between-group comparisons.
DISCUSSION
The main finding of this study is the demonstration of a
dopaminergic modulation in the rostral anterior cingulate cortex,
an area specifically implicated in emotional conflict resolution.
During our negative emotional Stroop task, drug-off parkinso-
nian patients displayed a relative hypoactivation in their rACC
compared with healthy controls. No significant difference within
the rACC activation was found between the HC and the drug-on
Table 4 | Brain regions activated during the emotional Stroop task
when only negative faces were analyzed in healthy subjects.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (negative
faces)
Cingulate cortex
Anterior cingulate L 32 6, 50, 4 55 6.73
R 24 6, 41, 7 11 5.46
Frontal cortex
Inferior frontal
opercularis
R 9 36, 11, 30 17 4.56
Middle frontal R 6 33, 2, 49 9 4.70
Parietal cortex
Superior parietal L 7 −18, −64, 52 13 4.80
Postcentral R 3 45, −22, 52 8 4.90
Precuneus R 30 15, −52, 11 18 5.09
Temporal cortex
Fusiform L 20 −36, −37, −18 17 5.34
R 20 27, −37, −18 50 6.70
Superior temporal L 22 −63, −16, 1 7 8.48
Insula R 13 45, 5, −2 37 6.49
Thalamus R 15, −16, 1 51 8.64
Occipital cortex
Middle occipital L 19 −27, −76, 33 42 9.01
Middle occipital L 18 −42, −73, 1 30 8.86
Middle occipital R 39 51, −52, 14 146 7.76
[C-I] (negative
faces)
No suprathreshold voxels
p < 0.001, k > 5, n = 12, uncorrected. Cerebral areas are defined by
the Automatic Anatomical Labeling. BA, Brodmann areas; C, congruent; H,
hemisphere; I, incongruent; k, cluster size (number of voxels); L/R, left/right;
MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal, and
dorsoventral.
patients, suggesting a normalization of the rACC activation deficit
after levodopa administration.
Our behavioral results indicated an abnormal negative ES
effect in drug-off patients. Controls and drug-on patients pre-
sented a negative ES effect, whereas drug-off patients did not,
suggesting that drug-off patients were less sensitive to nega-
tive emotional interference. Based on the anxiety and depressive
literature (Williams and Nulty, 1986; Becker et al., 2001), we
would have expected that the drug-off state, which increases anx-
iety and depressive mood, would be linked to an increased ES
effect. We would also have expected that drug-off patients took
longer to solve the ES conflict because of the abnormal activa-
tion of the rACC and the recruitment of additional brain cir-
cuits. Serra-Mestres and Ring (2002) showed that non-depressed
parkinsonian patients presented with greater interference to sad
words than did HC. However, their patients were tested while
on dopaminergic medication and it is difficult to compare their
study to ours, due to methodological differences such as the use
of another type of ES task and an alternative method for calculat-
ing the ES effect. An explanation to understand the diminished
emotional interference in our drug-off patients would be that,
although most dopamine neurons provide a reward signal, a few
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 164 | 8
Fleury et al. Emotional conflict in Parkinson’s disease
Table 5 | Brain regions activated during the emotional Stroop task
when only positive faces are analyzed in healthy subjects.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (positive
faces)
Cingulate cortex
Anterior cingulate L 24 0, 14, 30 31 5.49
Middle cingulate L 24 0, −1, 43 13 4.60
Frontal cortex
Superior frontal R 10 21, 56, 8 34 6.63
Parietal cortex
Inferior parietal R 7 27, −49, 56 61 5.34
Precuneus L 19 33, −70, 27 862 8.85
Temporal cortex
Fusiform L 37 −36, −46, −28 80 7.29
Middle temporal L 37 −48, −64, −2 7 5.19
Inferior temporal R 37 51, −43, −15 9 4.98
Basal ganglia
Caudate nucleus L −12, 5, −5 13 5.70
Pallidum L −12, 5, −5 13 5.70
Putamen L −12, 5, −5 13 5.70
R 36, 5, 11 8 4.96
Occipital cortex
Superior occipital L 18 −12, −91, 11 9 5.97
Middle occipital L 19 −36, −82, 24 36 6.58
Lingual R 19 15, −49, −2 84 7.51
Calcarine L 31 −12, −64, 17 60 8.40
Cerebellum L −18, −52, −21 18 5.14
R 27, −31, −21 15 4.70
[C-I] (positive
faces)
No suprathreshold voxels
p < 0.001, k > 5, n = 12, uncorrected. Cerebral areas are defined by
the Automatic Anatomical Labeling. BA, Brodmann areas; C, congruent; H,
hemisphere; I, incongruent; k, cluster size (number of voxels); L/R, left/right;
MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal, and
dorsoventral.
dopamine neurons (5–15%) are activated by primary aversive
stimuli (Schultz, 2013) This may partially explain why drug-on
patients are more sensitive to negative stimuli/distractors than
drug-off patients. Another hypothesis could be that Parkinson’s
disease enhances distractor resistance when patients are in their
drug-off state and that dopaminergic medication reinstates sus-
ceptibility to distraction (Cools et al., 2010). This could explain
the absence of negative distractor-related slowing in drug-off
patients, leading to relatively faster responding after distraction
than in controls and drug-on patients. Slowing was reinstated by
dopaminergic medication, as evidenced by the finding that the
patient responses in their drug-on state did not differ from that
of controls.
Lastly, another hypothesis to explain the decreased vulnera-
bility to emotional interference could be that the presence of
apathy in our drug-off patients enhances their negative emotional
blunting, making them less sensitive to negative distractors. Our
drug-off patients displayed a tendency to have impaired fearful
expression recognition and presented higher scores on the Apathy
Table 6 | Brain regions activated during the emotional Stroop task
with negative faces in drug-off patients.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (negative
faces)
Frontal cortex
Superior medial frontal L 8 −3, 32, 46 10 5.82
Temporal cortex
Inferior temporal L 37 −51, −55, −8 7 6.02
Hippocampus L 28 −24, −37, −8 15 6.28
Occipital lobe
Middle occipital R 19 42, −79, 14 11 8.32
R 19 30, −85, 20 7 5.09
Cuneus R 18 12, −94, 14 8 4.98
[C-I] (negative
faces)
No suprathreshold voxels
p < 0.001, k > 5, n = 10, uncorrected. Cerebral areas are defined by
the Automatic Anatomical Labeling. BA, Brodmann areas; C, congruent; H,
hemisphere; I, incongruent; k, cluster size (number of voxels); L/R, left/right;
MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal, and
dorsoventral.
Table 7 | Brain regions activated during the emotional Stroop task
with negative faces in drug-on parkinsonian patients.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (negative
faces)
Frontal cortex
Middle frontal R 46 45, 38, 17 5 5.05
Temporal cortex
Middle temporal L 22 −63, −31, 4 5 4.98
Inferior temporal R 19 39, −64, −8 13 7.71
[C-I] (negative
faces)
No suprathreshold voxels
p < 0.001, k > 5, n = 10, uncorrected. Cerebral areas are defined by
the Automatic Anatomical Labeling. BA, Brodmann areas; C, congruent; H,
hemisphere; I, incongruent; k, cluster size (number of voxels); L/R, left/right;
MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal, and
dorsoventral.
scale. Numerous studies have demonstrated an impaired recog-
nition of facial expression in Parkinson’ disease, especially for
negative emotions such as fear, disgust, anger, and sadness (Peron
et al., 2012). Clinically, apathy is identified as a reduction of
goal-directed behavior because of a lack of feeling, interest, emo-
tional reactivity andmotivation (Marin, 1991). Apathetic patients
have been shown to have a diminished capacity to process, iden-
tify and differentiate between favorable (positive stimuli) and
unfavorable (negative stimuli) outcomes and to adjust subse-
quent behaviors accordingly (Holroyd et al., 2002; Cohen and
Ranganath, 2007; Martínez-Horta et al., 2014). Research in the
field of apathy has shown impaired emotion recognition and
reward processing in the absence of deficits of higher cognition
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FIGURE 6 | Brain activation during the emotional Stroop task with
negative faces (contrast [I-C]) in the between group comparison
(Control vs. drug-off patients). p < 0.001, k > 5, nhealthy = 12,
npatients = 10, uncorrected. I; incongruent; C; congruent; LH, left
hemisphere; x, y, z: mediolateral, rostrocaudal, and dorsoventral; MNI,
Montreal Neurological Institute.
(Martínez-Corral et al., 2010; Lawrence et al., 2011; Robert
et al., 2014). In conclusion, apathetic drug-off patients are more
impaired than drug-on patients in distinguishing the valence of
emotional stimuli and in negative emotion recognition, which
could make them less sensitive to negative distractors. It is note-
worthy that the ES effect was absent during negative trials in
hypodopaminergic patients but present during positive trials,
probably because the emotional blunting in PD predominantly
affects negative emotions.
The abnormal negative emotional interference in our drug-off
patients could be linked with their relative rACC hypoactiva-
tion, because this area is specific to emotional conflict and was
hypoactive in drug-off patients compared with drug-on patients
and HC. Whalen et al. (1998) proposed that rACC activation
reflects the successful processing of emotional stimuli in the
service of facilitating task performance. The rACC appears to
decrease the weighting of irrelevant affective information in the
service of optimizing cognitive performance. In healthy volun-
teers, Bishop et al. (2004) found that the rACC was strongly
activated by infrequent threat-related distractors, consistent with
a role of this area in responding to unexpected processing con-
flict caused by salient emotional stimuli. Egner et al. (2008)
demonstrated that the rACCwas specifically implicated in the res-
olution of emotional conflict. In our patients, failure to activate
the rACC might then reduce the rACC control over negatively
salient task-irrelevant emotional stimuli, leading to a reduced
recruitment of the normal brain circuitry to overcome emo-
tional conflict and increase the cognitive processing load. In
our study, the dorsal ACC, a region implicated in both emo-
tional and non-emotional monitoring, was activated in HC in
the Incongruent vs. Congruent trials using all faces, negative
faces and positives faces. It was also more activated in drug-
on than in drug-off patients, suggesting an abnormal conflict
monitoring in hypodopaminergic parkinsonian patients. This
Table 8 | Comparisons between controls and drug-off patients: brain
regions activated during the emotional Stroop task with negative
faces.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (negative faces)
A. Controls vs. Drug-off patients
Cingulate cortex
Anterior cingulate R 32 6, 47, 4.4 16 4.75
Frontal cortex
Precentral R 4 39, −16, 49 6 3.67
Parietal cortex
Postcentral R 6 54, −7, 30 5 3.78
Thalamus R 12, −10, 1 11 4.76
B. Drug-off patients vs. Controls
No suprathreshold voxels
[C-I] (negative faces)
A. Controls vs. Drug-off patients
No suprathreshold voxels
B. Drug-off patients vs. Controls
No suprathreshold voxels
p < 0.001, k > 5, nhealthy = 12, npatients = 10; uncorrected. Cerebral areas are
defined by the Automatic Anatomical Labeling. BA, Brodmann areas; C, con-
gruent; H, hemisphere; I, incongruent; k, cluster size (number of voxels); L/R,
left/right; MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal,
and dorsoventral.
relative dorsal ACC hypoactivation might explain why drug-
off patients presented with rCCA hypoactivation via probable
top-down mechanisms.
The abnormal emotional interference effect and the rACC
hypoactivation seen in our drug-off patients were reversed after
dopamine administration, suggesting a dopaminergic involve-
ment in emotional conflict. To our knowledge, our study is the
first to evoke a specific dopaminergic modulation in the rACC
in parkinsonian patients. The ACC hypoactivation in drug-off
patients could be directly induced by the degeneration of meso-
cortical dopaminergic fibers. PD alters the mesocorticolimbic
dopaminergic system which consequently impairs the function of
the cingulate striatofrontal loop (Czernecki et al., 2002). Drug-
on patients did not differ from HC in terms of MRI activation
probably because dopatherapy doses were sufficient to restore
dopamine function in the mesocortocolimbic pathways in our
patients. The ACC receives one of the richest dopaminergic inner-
vations of any cortical area (Gaspar et al., 1989). The source
of ACC dopaminergic input comes from cell bodies located in
the ventral tegmental area (VTA). Using immunohistochemicals
methods, Raghanti et al. (2008) demonstrated a dense dopamin-
ergic innervation in the dorsal ACC (BA 32) in humans. The
mesocortical dopaminergic degeneration could then induce a lack
of rACC dopaminergic activation. The rACC hypoactivation in
drug-off patients could also be explained more indirectly by the
degeneration of dopaminergic cells originating from the VTA and
projecting to the orbitofrontal cortex (OFC). This denervation
could induce a dysfunction in the limbic loop of basal ganglia.
This circuit originates in the OFC and the ACC, and projects
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Table 9 | Comparisons between drug-on and drug-off patients:
cerebral sites of hemodynamic response during the emotional Stroop
task with negative faces.
Contrast Cerebral areas H BA MNI k T
coordinates
(x, y, z)
[I-C] (negative faces)
A. Drug-on vs. Drug-off patients
Temporal cortex
Inferior
temporal*
R 37 42, −61, −8 5 6.92
Cingulate cortex
Dorsal anterior
cingulate**
L 24 −3, 23, 19 21 4.28
Rostral anterior
cingulate***
R 32 9, 38, 1 5 3.59
B. Drug-off vs. Drug-on patients
Parietal cortex
Inferior
parietal**
L 40 −42, −52, 52 14 4.25
Temporal cortex
Inferior
temporal***
L 37 −45, −52, −8 5 5.18
[C-I] (negative faces)
A. Drug-on vs. Drug-off patients
No
suprathreshold
voxels
B. Drug-off vs. Drug-on patients
No
suprathreshold
voxels
*p < 0.001, **p < 0.005, ***p < 0.008, k > 5, n = 10, uncorrected. Cerebral
areas are defined by the Automatic Anatomical Labeling. BA, Brodmann areas; C,
congruent; H, hemisphere; I, incongruent; k, cluster size (number of voxels); L/R,
left/right; MNI, Montreal Neurological Institute; x, y, z, mediolateral, rostrocaudal,
and dorsoventral.
to the nucleus accumbens and the most rostral portions of the
ventral striatum (Oades and Halliday, 1987). The ventral stria-
tum projects in turn to the ventral pallidum, which then projects
to the substantia nigra pars reticulata, which finally projects to the
mediodorsal thalamic nucleus. This circuit is then closed by thala-
mic projections to the ACC and the medial OFC (Alexander et al.,
1986; Hamani et al., 2004). The rACC being a structure involved
in the limbic loop of the basal ganglia, the relative rACC hypoac-
tivation demonstrated in our drug-off patients could induce a
dysfunction of this circuit.
During the incongruent trials of our ES task, there was con-
flict between the automatic reading of emotional words (dis-
tractors) and the recognition of facial emotion. This situation
requires an implicit analysis, which is automatic, subconscious,
and rapid. This analysis probably involves the basal ganglia, which
are responsible for the automatic execution of learned motor,
cognitive, and emotional plans (Marsden, 1982; Alexander et al.,
1986). A basal ganglia limbic loop dysfunction would induce an
abnormal emotion regulation by cingulate failure to implement
control processes over affective distractive stimuli.
Neuropsychiatric fluctuations have been shown to be
an important component of levodopa-induced fluctuations
(Maricle et al., 1995a). They are related to levodopa dosing
(Maricle et al., 1995b). Parkinson’s disease behavioral distur-
bances can be described on a continuous spectrum ranging
from hypodopaminergic behaviors (apathy, anxiety, depression
and fatigue) to hyperdopaminergic behaviors (mania, impulse
control disorder, dopamine dysregulation syndrome, punding
and appetitive behaviors) (Ardouin et al., 2009; Lhommée et al.,
2012; Rieu et al., 2012; Castrioto et al., 2014). In our patients,
acute intake of dopamine replacement therapy improved the
Apathy and VAMS scores and was concomitant with normalized
ES task behavioral results and rACC activation. This finding
could provide a neurobiological basis for the physiopathology
of neuropsychiatric fluctuations. During their drug-off state,
our patients displayed higher apathy scores and VAMS affec-
tive and asthenia subscores, than drug-on patients. We have
discussed above how apathy could lead to decreased negative
interference in drug-off patients. The VAMS is designed to mea-
sure anxiety, mood changes and physical and mental sedation
in a non-specific way after the administration of drugs. It is
possible than the higher level of anxiety and sedation in our
drug-off patients was associated with the rACC hypoactivation
through disrupted attentional control over negatively salient
task-irrelevant emotional stimuli. This would be consistent with
studies addressing anxiety disorders such as Shin et al. (2001)
and Kim et al. (2008) who reported that posttraumatic stress
disorder patients presented decreased rACC functioning when
exposed to situations eliciting negative emotional conflict. In
terms of neuroanatomical network, our hypothesis that rACC
hypoactivation could explain at least in part the presence of neu-
ropsychiatric fluctuations, is consistent with Thobois et al.’s study
(2010) that demonstrated that patients with neuropsychiatric
fluctuations had greater mesocorticolimbic dopaminer-
gic denervation than patients without neuropsychiatric
fluctuations.
Our drug-off patients exhibited additional areas of cerebral
activation not seen in HC and drug-on patients, such as the left
superior medial frontal gyrus (BA 8) and the left hippocampus.
BA 8 is involved in the management of uncertainty. Increased
activation has been shown when subjects experience increasing
uncertainty (Volz et al., 2005), which appears to be the case
in our drug-off patients. The hippocampus is crucial for long-
term episodic memory (Bird and Burgess, 2008) and it has been
suggested that it facilitates predictions about upcoming events
(Buckner, 2010). It is possible that the limbic basal ganglia loop
dysfunction in drug-off patients is compensated by hyperacti-
vation of these two structures. When basal ganglia are ineffi-
cient, they cannot execute learned plans in an automatic manner
(Marsden, 1982) and drug-off patients rely on compensatory cor-
tical areas based on slow intracortical connections. Compensatory
activations have been frequently observed in drug-off patients
and impaired patterns of cortical activation tend to normalize
with both dopaminergic treatment and subthalamic deep brain
stimulation (Jenkins et al., 1992; Limousin et al., 1997).
A number of limitations of our study should be acknowl-
edged. Firstly, we report uncorrected statistics for our fMRI
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results. The small sample size did not allow for significant brain
activation when we applied correction of multiple comparisons.
Consequently, our results should be considered preliminary and
need to be repeated in a larger population. However, we adopted
a more stringent statistical threshold (p < 0.001) than would
normally be applied for corrected analyses. Each patient served
as his own control, meaning that differences between drug-on
and drug-off state may be highly significant in relatively small
samples. Secondly, we did not include a non-emotional Stroop
task for comparison with our ES task. It would have been
interesting to use the non-emotional Stroop task described by
Egner et al. (2008). Without this task, it is difficult to dissoci-
ate the proportion of behavioral slowdown during incongruent
trials, due to non-emotional and to emotional interferences.
It is also difficult to dissociate the neuroanatomical networks
recruited in conflict depending on the nature (emotional or
non-emotional) of the conflict. Nevertheless, numerous stud-
ies, such as the paper by Egner et al. (2008) have precisely
defined which regions are specifically activated in non-emotional
and emotional conflict tasks, making the rACC hypoactiva-
tion in our drug-off patients specific for emotional conflict
resolution.
In conclusion, our study suggests that emotional conflict pro-
cesses could be dopamine-dependent. Drug-off parkinsonian
patients demonstrated a relative underactivity in the affective
subdivision of the ACC (rACC) during a negative emotional
interference task, which was not seen in the same patients in the
drug-on condition, nor in healthy controls. However, our results
should be considered preliminary, as further trials with larger
sample sizes are required. Rostral ACC hypoactivation could
be due to the degeneration of dopaminergic mesocorticolimbic
pathways.
In light of the role of the rACC in mediating affec-
tive and motivational behaviors (in particular in emotional
conflict resolution), we suggest that deficient rACC activa-
tion in hypodopaminergic parkinsonian patients might explain
their adaptational difficulties in response to negative emo-
tional distractors and promote neuropsychiatric fluctuations
such as apathy, anxiety or depression. Our data support the
hypothesis stipulating that neuropsychiatric fluctuations have
a dopaminergic substrate and reinforces the knowledge that
adjustments of dopaminergic medication might be helpful for
the treatment of neuropsychiatric fluctuations in Parkinson’s
disease.
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